Active TopicsActive Topics  Display List of Forum MembersMemberlist  CalendarCalendar  Search The ForumSearch  HelpHelp
  RegisterRegister  LoginLogin

Sector talk
 The Equity Desk Forum :Investment Ideas - Creating winning portfolios! :Sector talk
Message Icon Topic: Identifying a Stock-Do's and Dont's Post Reply Post New Topic
<< Prev Page  of 6 Next >>
Author Message
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:37am

Identifying a hotel stock: Do's and don'ts
 

How to analyse a company? This is the first question a retail investor has in mind before taking investment decisions. In continuation to the article last week on ways and means to identify an FMCG stock, consider key factors to be borne in mind when it comes to identifying a Hotel stock.

Profile
Unlike FMCG, auto or even banking, hotel industry is more global in nature. As a result, geo-political events, say September 11 attack, play a vital role in influencing tourist arrivals into and outside India. The ability of a player in the sector to attract the bulk of tourists coming into India and travel within the Indian border depends on select factors. These include the strength of the property portfolio (whether near a heritage site, near airport, commercial capital and so on) and brand awareness. For example, Taj (Indian Hotels) and Oberoi (EIH) are generic names in India when it comes to premium hotel chains.

Normally, hotels are capital intensive in nature having long gestation periods, which not only has a bearing on the free cash flows of hotels but also affects the return on capital employed (ROCE) for a period of time.

Revenues for a hotel chain are a factor of occupancy rate (number of rooms occupied) and average room rates (popularly termed as ARRs). Revenues are also derived from food and beverages, management services and so on. Consider key factors that influence occupancy rate and ARRs.

Occupancy rates
Consider the chart below. The hotel sector benefits from both holiday and business travel. Holiday travel in India is generally seasonal in nature. Historically, over 60% of total tourist arrivals into the country is during the period between September-May. On the other hand, business travel is a factor of various factors. This includes government’s effort to promote India as a tourist destination, long-term economic growth prospects and higher foreign participation arising by hike in FDI and FII holding limits in Indian companies and joint ventures.

For the last few years inbound (coming into the country) tourists have been around 2.5 m while out bound (going out of the country) tourists have been around 30 m. Out of the inbound, a large part of the travelers to the country are of the business class, while the rest are leisure segment. Connectivity between cities in the form of better road infrastructure, airports and seaports also play a vital role in increasing the share of India in the global tourist pie. India is a country of various cultures and has some of the world-class heritage sites, which when promoted in the global arena, can attract the global tourist.

On the domestic leisure travel front (i.e. people traveling within India for both commercial and leisure reasons), there is lot of seasonality involved. Besides, as income increases, aspiration level of the population also gains ground and consequently, spills over into better occupancy rates for hotel chains. While it may not be true for luxury hotels, players in the budget hotel sector and time-share segment benefit in a large way.

Average room rates (ARRs)
Without getting into complexities, there are three classes of rooms in a hotel i.e. business, leisure and luxury. It is important to understand that room rates are less elastic to a fall in price at the higher end of the segment (luxury) than at the lower end of the spectrum (business/leisure). Therefore, even in a downturn, players like Indian Hotels are relatively able to maintain higher operating margins than EIH. Established players in India have an edge over MNCs and the unorganized segment, due to properties near heritage sites.

Competition also plays a vital role in determining the sector’s ARRs. Currently, the big hotels have average occupancies of 60%. This points to excess supply. That itself is sometimes a dampener on ARRs.

The global scene
International hotels are derive a big chunk of revenues from casinos and betting arenas. Margins in this segment are also higher. But for Indian hotel majors, setting up casinos and betting arenas is not allowed according to Indian laws. However, when domestic hotels are compared to international hotels then they are fairly competitive in terms of average room revenues.

How to put a value to a hotel chain? Net Asset Value (NAV) is the answer.

For arriving at a Net Asset Value

 

Setting up a 5 star hotel

= Rs 30-35 m*

Add

= Cash + investments

Deduct

= Debt

Net Asset Value (NAV)

Total

Divide

No. of Shares

NAV per share

= Rs x

Compare with current market price

 

* depending upon the area of setup

 

Coming to the NAV of domestic hotels, on the basis of replacement cost method let us see the value of the hotels at current prices. By NAV we can arrive at the actual value of the properties of the hotels. Based on that, NAV per share can be calculated, which gives the actual value the shareholder should be paying for being a part of the company. However, for hotels, which have been in the industry for a period of time their NAV would be on the higher side, as the property bought would be at a much lower rate than the present times. Like for instance the NAV of Taj and Oberoi Hotels would be higher than that of ITC Hotels and other hotels.

Key things to look at before investing in a hotel stock

1.      What are the strategy and the capex plans of the company over the next 5-10 years? As mentioned earlier, hotels are capital intensive in nature having long gestation periods, which not only has a bearing on the free cash flows of hotels but also affects the return on capital employed (ROCE) for a period of time. So the bigger the capex plan, the more caution one should exercise. This criteria is favorable for established hotel chains.

2.      Economic cycles also determine earnings prospects (during a downturn, properties are cheaper and hotel chain generally tend to increase capacity). Moreover, in tough times like September 11, hotel stocks take a beating. It is at this time that the established players should be looked at, for when the concerns fade away, these will be the first ones to benefit from an economic upturn.

3.      A hotel chain should not be leveraged on any specific segment i.e. luxury or leisure. Though elasticity is lower at the premium end, when tourist flow is affected, this player could be the worst hit. Diversification reduces volatility in earnings, to an extent.

While growth prospects continue to remain heartening, the sector is typically a high-risk-high-return game due to the vulnerability to external factors. Buyers beware!

 

India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:39am

Identifying a domestic pharma stock: Do’s and don’ts
 

There is a famous saying that ‘while investing in equities, investors are actually buying the business of the company and not the scrip per se’. If this is the case, there are lots of complexities involved when it comes to picking a pharma company for investment. Here is an attempt to enable a retail investor to identify a domestic pharma company for investment.

As can be seen from the chart above, Indian pharma companies derive revenues from the domestic and international market.

Domestic market:

The domestic market can be broadly divided into two categories i.e. bulk drugs and formulations. Two key factors that have to be borne in mind are that the Indian pharma market is highly fragmented due to the lack of a patent regime. Therefore, pricing power is very less and any player can duplicate a product in a very short span of time.

Coming to bulk drugs , they primarily represent the basic raw materials used in the manufacture of a formulation. If the company is engaged in the bulk drugs business, what the investor must look into is the extent of the Drug Price Control Order (DPCO) cover on the company’s products. DPCO is a government regulation that fixes the ceiling prices for the bulk drugs. Thus, a company manufacturing drugs covered by the DPCO loses its pricing power, resulting in lower margins. Therefore, lower the exposure to products covered by DPCO, the better.

Another important thing to be looked at is whether the bulk drug company carries out any contract manufacturing activity. In this case, the company acquires a contract from another company for manufacturing its products, which will subsequently be sold by that other company. But why contract manufacturing? Low labour costs and US-FDA approved plants are advantages on which the Indian pharma companies can capitalize and increase revenues.

On the other hand, if a company is dependent on formulations, the investor must ascertain the extent to which its products fall under the National Pharmaceutical Pricing Authority (NPPA) cover . NPPA fixes the ceiling price for formulations. Thus, as in the case of bulk drugs, lower the exposure to products covered by NPPA, the better for a formulations company. Here again the company could enter into a manufacturing contract with an MNC.

Even in formulations, there are two broad categories i.e. lifestyle segment and traditional segment. Lifestyle segment comprises of drugs that are used to cure diseases that are linked to stress, urbanization and changing diet pattern and lifestyle of high-income level population. Major drugs in this segment are anti-diabetes drugs, cardiovascular system drugs, gentio-urinary and sex hormones drugs, CNS drugs, anti-depressants and psychiatry. These segments are not price sensitive and are less fragmented.

The traditional segment , on the other hand, comprises of anti-infectives, pain management and anti-biotics. This segment is highly fragmented. Thus, if a company has higher exposure in the lifestyle segment, the growth prospects and margins of the company will be higher.

International market:

As far as international markets are concerned, as apparent from the graph above, is broadly divided into three categories viz. generics, Novel Drug Delivery System (NDDS) and developing a New Chemical Entity (NCE).

Generics are a bio-equivalent of a patented drug. Simply, if ‘erythromycin’ is coming out of patent, a company can launch the same erythromycin, but with a different composition (end effect however, is the same). Every year, a number of drugs come out of the patent regime. So, a company in India who does not have the R&D capabilities or funds to invest in R&D launches the generic version of the drug that is coming off patent. The advantage here is that the Indian company need not invest large sums in R&D. However, legalities are very complex (like Para I to IV) and time consuming. When the company’s research is at a very nascent stage, it concentrates on the sale of off-patent drugs.

 

Starting from Para I to III, there is no restriction on the number of players that can enter the market (competition is global in nature). Margins therefore, are not very high. It is basically a volume driven strategy.

Gradually, as the company grows, it shifts its focus onto developing a new drug delivery system for an existing drug and also challenges existing patented drugs by introducing their bio-equivalents. A company files an ANDA for NDDS when it has developed a new method or dosage of delivering a patented drug to the patient. When a generics company challenges an existing patent, it is required to prove that the patent is not infringed or that the patent is invalid. He is thus required to prove that his drug is bio-equivalent to patented drug. If successful, the company gets a 180-day exclusivity period during which it has the sole right to sell the drug in the market. Consequently, the company enjoys very high margins during this period of exclusivity. However, the litigation expenses are very high in such a case.

An investor has to put more emphasis on the total number of Para 4 ANDA filings rather than the aggregate number of ANDAs filed. Further, the investor should look into the long-term prospects of the company and not base his decision on the outcome of a single legal suit, or a single blockbuster generic success.

Major aspects that need to be observed:
Government policies have a major influence on the domestic pharma sector. As can be seen from the table below, due to the absence of a good health insurance policy, India has one of the lowest public health expenditure as a percentage of GDP. Moreover, even on the health infrastructure front, India has a long way to go as compared to other developing nations.

A long way to go

Country

Public health expenditure
as a % of GDP

Per capita health
expenditure ($)

No of hospital
beds per 1000 people

India

0.8%

94

0.8

Brazil

2.9%

453

3.1

China

2.0%

143

2.9

Malaysia

1.4%

189

2.0

USA

5.8%

3950

3.7

Source: World Bank website

Management is the most crucial aspect for any company’s success. While this is true for every industry, it attains even more significance in the pharma sector. Being an extremely specialized sector, it is very important that the management has the requisite expertise and skills to handle the complexities involved it this business. Thus having ‘the right person at the right place’ is key to the success of a company. Watch out for this in the annual reports.

R&D expenditure as a percentage of revenues is a very useful tool for evaluating the company’s R&D thrust. As product patents come into effect, only companies with high R&D investment will survive. Thus, higher the ratio, higher will be the R&D focus of the company and the better placed will it be to face the uncertainties of the future. Of course, R&D has its inherent risks as well.

Last but not the least, keeping aside growth prospects, the sector has significantly high-risk profile due to the dynamism. Even erstwhile big names in the global pharma industry like Upjohn, Burroughs, Knoll, SmithKline Pharma, Pharmacia and Hoechst, found the going tough alone. Ultimately, they had to join hands with bigger players in a bid to survive. Indian companies are still relatively small. If this is the case, a retail investor has to exercise caution. So ‘pick and choose’.

 

 

There has been a lot of hoopla about the need to invest in Research & Development (R&D) by the Indian pharmaceutical companies to remain competitive after the product patent regime is implemented in India in 2005. We feel the importance laid on R&D by domestic pharmaceutical companies can be better understood by understanding the global R&D scenario.

The Global R&D process

It can be safely said that the pharmaceutical industry is more research-intensive, as compared to the any other industry. One of the activities of research and development of the companies is directed towards finding newer molecules as a cure for diseases.

The innovator company synthesizes a New Chemical Entity (NCE), which can probably be a cure for a disease. The synthesis of a NCE takes place in the pre-clinical testing period. The innovator company, after synthesizing a NCE, files an Investigational New Drug (IND) application, prior to commencing clinical trials. The FDA grants patent to the NCE at this stage.

The drug discovery process

Source: PhRMA

As can be seen above, after the IND filing it takes around 10 years for a NCE to pass through the three phases of clinical trials, attain the final FDA (Food & Drug Administration) review approval and post marketing tests to ultimately launch the product. As already mentioned, the FDA grants patent to the NCE at the time of the IND filing and the duration of such patent is around 20 years. In this context, a drug ultimately enjoys patent protection after its market launch for only around 10 years, to recover its costs.

After the expiry of a patent, generic companies immediately launch the products and consequently, there is a sharp downward correction in the price of the particular drug. The fall in prices can be as much as 90% depending upon the number of generic manufacturers and the nature of the drug. The fall in prices also result in a fall in the margins for the branded drug. The generic market has witnessed significant growth over the years. While generics account for around half of the prescriptions in the US, it accounts for only around 10% of the pharmaceutical market in the US in value terms. The reason for the same is low realizations of generics vis-à-vis patented drugs.

Generics

A generic drug has similar effects in terms of its rate and extent of absorption of an approved product, which has to be proved by the generic company. In other words the generic drug has similar effects in curing a disease as the approved product. The generic approval process is called Abbreviated New drug Application (ANDA).

While filing an ANDA, the generic company has to choose one of the following four options (referred to as paras)

  • Para I - The drug has not been patented
  • Para II - The patent for the drug has already expired
  • Para III - The patent for the product exists but the generic company wants to enter the markets after the date of patent expiry passes.
  • Para IV - Patent is not infringed upon or is invalid

In a Para III filing the company acknowledges the patent of the approved drug and intends to enter the market after the patent for the approved product expires and there exists a scenario of falling prices for the drug, whereas in Para IV filing the company claims that the generic product of the company does not infringe upon the existing patent or the patent of the branded product is invalid and the company strives to win an exclusivity of 180 days during which the margins for the product are very high. For instance, recently Dr. Reddy's filed an application with the US FDA to market a generic form of Eli Lilly's schizophrenia drug ‘Olanzapine’ in the United States.

In all the generic filings, the FDA has 180 days to deem the generic application complete and accept it for review, or incomplete and reject for filing.

In case of Para I and Para II filing, once the application is deemed complete, it is simply processed for approval. In case of Para III the application is processed for approval, however its approval status depends upon the products patent expiry. Apparently Para IV filings are the most lucrative, tedious, time consuming and expensive of the above.

The approval process of the Para IV is as provided below:

Post 2005 scenario

After the patent regime is implemented in India in 2005 no company would be allowed to launch products patented after 1995. In other words Indian companies will still be allowed to launch NCE patented before 1995 in the market. As already discussed it takes around 10 years for a NCE to be commercially launched, as a result of which the Indian companies will have additional cushion in terms of time to gear up fully for the patented regime

Already Indian companies have forayed into basic research and their success has so far been very very limited. However, as it is said, the secret of getting ahead is getting started and every small step by Indian companies will raise their probability to succeed in the future.

 

The Indian pharmaceutical industry has come a long way since 1970 when the government introduced regulation in the pharmaceutical industry in the form of Drug Price Control Order (DPCO) and more recently, through the price-monitoring agency-National Pharmaceutical Pricing Authority (NPPA). These regulations were essentially to control the prices of drugs in the domestic market. This has helped the industry in providing quality drugs at reasonable prices. But with India now required to comply with the WTO regulation of providing product patents by 1st January 2005, the face of the Indian pharmaceutical industry is about to change in the coming future.

Indian companies have traditionally concentrated on low priced generic drugs. They were thus not able to obtain critical size and hence restricted their research expenditure to low cost research activities such as reverse engineering of patented products. The R & D expenditure in India as a percentage of sales was only 2% in FY00 as against 15% for the global pharmaceutical majors. However, after 1st January 2005, Indian companies will not be able to reverse-engineer patented products and will have to increasingly invest in research to develop new products. There is hence an apprehension that Indian companies might find it difficult to survive in the post-patent period. In this scenario, let us analyse the various avenues open to Indian companies once the patent regime comes into effect.

Licensing out an NCE:
Indian companies could use their expertise in chemistry and process development to develop New Chemical Entities (NCE). NCE is a chemical molecule developed by the innovator company in the early drug discovery stage, which after undergoing clinical trials could translate into a drug that could be a cure for some disease. Synthesis of NCE is the first step in the process of development of a drug. Once the synthesis of the NCE has been completed, Indian companies have two options before them. They can either go for clinical trials on their own or license the NCE to another company. In the latter option, Indian companies can avoid the expensive and lengthy process of clinical trials, as the licensee company would be conducting further clinical trials and subsequently launching the drug. Companies adopting this model of business would be able to generate high margins as they get a huge one-time payment for the NCE apart from entering into a revenue sharing agreement with the licensee company.

For example, Dr Reddy’s Laboratory has licensed its NCE for diabetes DRF 2725 to Novo Nordisk and received a milestone and upfront payment of Rs 334 m and its NCE for Type 2 diabetes DRF-4158 to Novartis Pharma AG for Rs 55 m during the financial year 2002. The following table shows the major drugs licensed by Indian companies.

Innovator Company

Licensed to

Name of the NCE

Segment

Dr. Reddys Laboratory Ltd.

Novartis Pharma AG

DRF-4158

Anti-Diabetes

Dr. Reddys Laboratory Ltd.

Novo Nordisk

DRF-2725

Anti-Diabetes

Dr. Reddys Laboratory Ltd.

Novo Nordisk

DRF-2593

Anti-Diabetes

Ranbaxy Ltd.

Bayer AG

CiproXR

Anti-Infective

However, there is a risk of failure of the drug at any of the phases of the clinical trials and could adversely affect the performance of the company. For instance, the phase 2 clinical trials of Dr. Reddys Laboratory’s NCE DRF-272 (Ragaglitazer), being carried out by Novo Nordisk, were suspended resulting in a loss of huge potential revenues for the former, had it reached the commercial stage.

In the other option, Indian companies could instead of licensing out the NCE, carry out the entire process of clinical trials, obtain the required regulatory approvals and launch the drug in the market. The company would have the patent for such a drug and hence be able to enjoy marketing exclusivity for a long period, in which time they are able to generate large revenues. The margins in this kind of initiative are also comparatively large. Ranbaxy Ltd. has taken lead in this field. Phase 2 clinical trials for its first NCE for curing Urological disorders, RBx-2258 is being carried out at different centers in India. Another molecule RBx-6198 is in its’ early discovery stage.

However, passing of the NCE through various phases of clinical trials takes atleast 8-10 years and entails huge R & D expenditure. It is estimated that on an average, development of a new drug costs around US$ 400 m. Moreover, risk of the new drug failing at any of the different stages of clinical trial is also extremely high and the company could loose the entire R & D investment made by it on the failed NCE.

Contract Research:
The availability of highly skilled and low cost research specialists and scientists makes India an ideal destination for many MNCs for outsourcing their research activities. Indian companies could thus act as Contract Research Organisations (CRO) and carry out research on behalf of the MNCs. Nicholas Piramal India Ltd. has recently established a CRO, called Wellquest, for conducting research on behalf of foreign companies as well as for generic research for Indian companies. Many bulk drug producers like Morpean and Suven Pharma are also evaluating the possibility of venturing into this field, as the margins are high.

Contract Manufacturing:
India has a cost advantage in the manufacture of drugs. The cost of setting up an FDA approved plant in India is almost half of that in the USA. With the government now allowing 100% FDI, many foreign companies are planning to outsource the manufacture of their off patent drugs to Indian companies and concentrate more in the development of new products. For Indian companies, this is an area of large potential. Indian companies have already started capitalizing on this opportunity. Nicholas Piramal Ltd. has recently entered into an agreement to manufacture various Allergen Inc products.

Co-marketing:
One of the major plus points of the Indian pharmaceutical industry is its’ well established marketing and distribution network. For a commission, Indian companies can capitalize on their existing distribution network and enter into marketing agreements with other companies that have a product but do not have the sales force required to market the same. Wockhardt has entered into a marketing agreement with Bayer AG for the marketing of the anti-diabetic drug Acarbose.

Generics:
Finally the Indian companies can continue to specialize in generic drugs and formulations. A company can wait for the patent of a drug to expire and bring out the generic version of the same. It is estimated that 15 of the 35 block bluster molecules will be off patent by 2005. Moreover, there is increasing pressure on the US government to reduce healthcare expenditure by enabling a faster generic entry in the markets. This gives the generic companies the opportunity to flood the US markets with quality generic drugs at competitive prices. The generic drugs business is, however, characterised by low pricing and hence the margins are bound to be low. The following graph indicates the value of the drugs likely to go off patent by 2005. However, it should be noted that the generics sales would not increase by such high amounts as the generics are sold at much lower prices as compared to their patented counterparts.

Indian pharmaceutical industry is highly fragmented with 23,000 players and no company enjoys more than 7% market share. However, with the introduction of product patents, many companies have started going in for Mergers and Acquisitions and thus gain synergies in research and development, cut costs, sustain revenues and increase market share. This will also help the companies in being better prepared once the product patent is introduced. Recognizing this, Nicholas Piramal India Ltd. acquired Rhone Poulenc in FY02 and the pharma business of ICI (India) Ltd. and Global Bulk Drugs and Fine Chemicals Ltd. in FY03.

From this article, we see that there is a wide range of business models that Indian companies can adopt in order to survive the post 2005 era. Thus companies that are able to recognize their strengths and capitalize on the same are the ones that will survive. Many Indian companies have realized this and are in the process of identifying the business line that would yield optimum returns. From here on, success for Indian companies in the pharmaceutical industry will be a factor of viable long-term strategies.

 

 

India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:42am

Identifying a power stock: Do’s and Don’ts
 

“When you think of digitizing India there will be a massive amount of power required and I pray to this government that you have to push and push and push to invest in infrastructure – Mr. Jack Welch”

Profile
Power can be generated from water (hydro), thermal (coal or naphtha), wind and nuclear. Since the Indian power sector has not been opened up for private sector participation in its true sense, the centre and state governments have a major role to play. It is a politically sensitive sector i.e. tariffs cannot be hiked as the vote bank could be affected.

A power company can be a generator, a transmitter, a distributor or a combination of all three. Barriers to entry are high because it is capital intensive and regulated. While technology in state government undertakings is poor, it will play a big role in the future, as consumers will require good quality and uninterrupted supply of power. Currently, in India, we have 1,07,533 MW of generation capacity out of which private sector contributes 11%. Let’s have a look at the revenue model for a power company.

Total revenues = Revenues from generation + transmission + distribution.

Generation
For a company involved in generation of power, revenues will be a function of electricity generated and tariffs applicable. Generation of electricity is a function of PLF (plant load factor) and the capacity installed. PLF, in simple words, is like capacity utilisation. The level of PLF varies depending upon the kind of generation plant. Generally, a hydro power plant or a wind energy plant have low PLF (industry average 35%-50%). Thermal and nuclear power plants have higher PLF (industry average 50%-65%), which ultimately results in higher production.

Investment in capacity in the power sector depends on various factors like: demand-supply gap (in simpler words we can say deficiency), availability of funds, economic growth and regulatory framework. All these factors are inter-related to some extent.

Demand and supply
One critical factor when it comes to analyzing a power company is the fact that demand expands as per supply. There is nothing like a ‘market size’ per se. The level of the growth in the industrial sector, per capita consumption of consumer durable and electronic goods would indicate the growth potential. For instance, the penetration level of air conditioners in India is just 0.5%. If more people buy A/C or television or refrigerator, demand for power will increase. Therefore, as far as demand-supply gap for a developing economy like India is concerned, it is irrelevant. The country is power deficient.

Availability of funds
As we had mentioned before, the sector is capital intensive. It costs almost Rs 40 m to Rs 45 m to set up one megawatt (MW) of capacity. If a company is planning to increase capacity by 1,000 MW, it requires Rs 40 bn. From a retail investor perspective, look at the cash balance and the current debt to equity ratio of the company from the balance sheet. This will give an idea whether the company really has the muscle power to expand the stated capacity in the time frame mentioned.

Economic Growth will lead to increase the purchasing power of the people, which will raise the living standard and in turn increase electricity demand. So, the circle starts again.

Regulatory framework
If a company is just into generation, it has to supply to a distributor for realising value for the quantity of power sold. If the distributor is a SEB (i.e. state electricity board), the chances of delayed payment are high, as SEBs are in poor state. Failure to receive money from SEBs could hamper a company’s capacity expansion plans.

Having looked at the capacity side, consider factors involved on the tariffs front.

For a generation company that supplies electricity to a SEB, the respective state governments fix tariffs. However, a power generation company can also supply to the national grid at a specific rate. The national grid say, Power Grid Corporation, in turn could take the onus of meeting SEB requirements. While the advantage is lower risk of delayed payment and fewer losses on account of T&D, the disadvantage is that the tariffs are lower compared to a T&D player. To put things in simple terms, the generation company gets a specific rate on power supplied whereas it is not the case with a T&D player where there is differential tariff structure.

For a distribution company (like Tata Power or BSES in Mumbai), tariffs are different depending upon the customers. Usually, industrial units are charged higher as compared to households (cross-subsidisation). Agricultural sector is a mixed bag. While some states actually charge for power supplied (like Tamil Nadu), in most other states, it is free. The advantage for a generation and distribution company is that it can pass a rise in cost to customers in a deregulated market. However, power theft and default rates are high for a distribution major. Watch out for this as well.

Transmission
There can be independent transmission companies as well (like backbone service providers in the telecom sector). The revenue model is similar. A transmission company buys power from a generation company and hands it over to SEBs or a distribution company. When it comes to advantages, it is like less capital and technology intensive. But a transmission company faces the risks of default of payment by a distributor, high leakage losses and a cap on transmission charges. Approximately 30%-35% or power generated is lost in transmission currently.

Distribution
The distribution company can also generate electricity in-house, but the process remains same. Distribution Companies have pre-defined areas called ‘circles’ where they can supply electricity. For a distribution company, metering plays a vital role. Metered units = Inhouse power generated (if any) + Power sourced from a generator to meet additional requirement – T&D losses. A major concern for the Indian distribution companies is heavy T&D losses due to poor infrastructure. Due to weak anti-theft laws, 10%-15% of power supplied is lost in distribution.

Key operating and financial parameters to be looked at

§         Guaranteed return: A power company is guaranteed a certain return on capital employed on generation by the government. If input cost increases, a generation company passes on the cost through increasing the capital employed to maintain margins. Watch out whether there is a possibility of the government reducing the guaranteed return. If it does, it could affect profitability of a power company.

§         Valuing a power company: Since this sector is all about assets, arriving a NAV is important from a retail investor perspective. It is simple and information is available in the balance sheet itself. As we mentioned earlier, it costs around Rs 40 m – Rs 45 m to set up one MW of capacity (including distribution costs). For a pure generation company, it could range between Rs 20 m to Rs 25 m.

NAV = (Capacity * rate per MW depending whether it is pure generation company or a combination of both) – Debt + Cash. Divide NAV by number of shares outstanding to get an approximate NAV. This could serve as a benchmark.

§         Dividend yield: Since power companies have strong cash flows, dividend is one key parameter to look at. Dividend yield is a very useful parameter. But if the company is in the process of expanding capacity, the dividend payout is unlikely to be high in initial years.

Apart from what all has been said above, the investor needs to look at the past record of the management, its vision and its focus on business. After all it’s the management of the company who is the final decision-maker and the future of the company solely depends on the decisions taken by it.

 

India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
omshivaya
Senior Member
Senior Member
Avatar

Joined: 06/Sep/2006
Location: India
Online Status: Offline
Posts: 5966
Quote omshivaya Replybullet Posted: 01/Feb/2007 at 1:44am
Keep it coming Sandeep ji.
The most important quality for an investor is temperament,not intellect.A temperament that neither derives great pleasure from being with the crowd nor against it
IP IP Logged
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:44am

Identifying a refinery stock: Do’s and Don’ts
 

It is often said that the dynamics of the world economy are often altered due to the crude oil price movement. As a result, the dynamics of companies operating in this sector are very different. Here in this article, we deal with key factors that impact the performance of petroleum products companies.

Profile
Petroleum products can be broadly classified as kerosene, diesel, petrol, naphtha, aviation fuel (ATF) and liquefied petroleum gas (LPG). As the name itself implies, crude is ‘refined’ into various usage based products or distillates. Without going into much complexity, the three broad classifications are heavy distillates (furnace oil and bitumen), middle distillates (diesel, kerosene, aviation fuel) and light distillates (LPG and petrol). This is how most of the companies in India classify products in their balance sheets. Margins are higher in middle and light distillates.

Globally as well as in Indian markets, government has a vital role to play in internal policies and external diplomatic relationships. This is because crude oil involves diplomatic relationships on the sourcing front and outgo of foreign exchange. On the other hand, the government also plays a key role in fixing excise duties on petroleum products. Moreover, it also deals with basic requirements of industries and public in general.

Revenues
Revenues are a function of volumes and realisations. Lets look at the volumes side first.

Volumes
Volumes in case of oil sector are linked to economic growth. Why? Economic growth, as you know, is linked to the performance of the agriculture, industrial and services sector. When growth gains momentum , demand for petroleum products tends to increase and vice versa, as it is a source of energy. This is not just restricted to the industrial side but also from the retail market (more units of cars and CVs sold, higher is the demand for fuel).

·         The industrial side
Demand for petroleum products is relatively inelastic to change in prices. In case of industrial, the key user segments are fertilizer (naphtha or natural gas), utilities (naphtha or natural gas) and aviation (ATF). Any increase in power capacity, growth in tourism sector and better agricultural sector performance has a positive impact on petroleum companies. Hence, one should keep abreast of developments in these user segments. However, alternate sources of fuel like natural gas may adversely affect volumes growth.

·         The retail side
On the retail sector, demand drivers are primarily linked to income levels at the hands of people. Higher income growth will lead to a rise in automobile demand as well as usage of LPG. On the auto sector front, diesel accounts for an estimated 40%-45% of total consumption. Kerosene and petrol account for 8% and 13% of consumption respectively.

Realisation
One cannot however, ignore the realisation angle. Earlier before deregulation in 2002, the government fixed prices of petroleum products. Prices were cross-subsidised . While petrol prices were higher compared to the actual cost, kerosene, diesel and LPG were sold at lower rates. But with the dismantling of APM (administered price mechanism), prices of these products are now linked to international crude prices. What this means is that whenever crude prices go up, petrol and diesel prices will mirror the trend. Though LPG and kerosene continue to be subsidised, the government has decided to remove the subsidy in a phased manner.

As mentioned earlier, government has an active role to play in this sector. Hiking diesel and petrol prices is a politically sensitive issue, which could affect the vote bank of any ruling party. In this context, prices of LPG, diesel and kerosene are not based on reality. Government intervention and policies play a major role in determining the prices and hence one should be aware of these developments.

Expenses
Since the prices of crude oil (major raw material) are linked to international prices, one must be aware of the prevailing prices internationally. Crude oil price is known to be very volatile (has moved from a low of US$ 10 per barrel to a high of US$ 35 per barrel) and is a function of demand and supply and also various geo-political situations. This apart, currency fluctuations alter the cost significantly. Let’s take a hypothetical example to understand these currency fluctuations.

Consider that the currency rate last year was Rs 49 per US$. The crude imports were about 81.2 m tonnes. Crude prices were at US$ 27 per barrel. Now one year later, we assume that crude prices are at the same levels but the rupee has appreciated by about 6%. Then, the company that is sourcing crude will have to shell out less for the same quantity resulting in a saving of Rs 47.2 bn. Since refineries are now allowed to source crude independently, exchange rate fluctuations impact profitability.

Key parameters to look into…
Consider key things that one should look while analyzing the companies in the sector.

·         Refining capacity : To set up a 1 MT plant, an investment of Rs 10 bn is required. Of course, the cost goes down if one goes in for a higher MT plant. So, it is a very capital-intensive industry and therefore, barriers to entry are high. Besides, with environmental regulations expected to become stricter, watch out for the company’s status on this front. Higher contribution from light and medium distillates is beneficial. Higher the refining capacity, higher the chances of altering product mix to derive more revenues. Though branding is possible, petroleum products are largely a commodity.

·         Integration benefits: Another key aspect is to note whether a company is integrated forward (distribution), backward (crude oil exploration) or a standalone player (only refining). Standalone players have less bargaining power, as products have to be sold to consumers through an external distribution network. Integrated players have an upper hand.

·         Distribution network: Petroleum products are usually sold through retail outlets that offer lot of leveraging opportunity for a company. Look out whether the company owns most of the outlets or it is franchise based. It costs Rs 20 m to set up a retail outlet and if a company owns a major part of the distribution, it can be valued accordingly. By leasing out part of its distribution, a marketing company can maximize revenues (like ATMs).

·         Valuations: Since it is a commodity sector, valuations should be in line with the economic growth in the long-term. But some companies get lower valuations due to the PSU status . But if a player in integrated, valuations tend to be on the higher side. Price to earnings and price to book value are useful tools.

And last but not the least, the management’s past track record . Though the government owns some companies, watch out whether the management has been proactive in branding the product and new capacity expansions. But government intervention is still a reality and therefore to that extent, caution has to be exercised.

 

India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:45am

Omjee,

 
TED SAYS SPAMING NOT ALLOWED WHEN I AM POSTING THIS.
India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
India_Bull
Senior Member
Senior Member
Avatar

Joined: 19/Sep/2006
Location: United States
Online Status: Offline
Posts: 2296
Quote India_Bull Replybullet Posted: 01/Feb/2007 at 1:46am

Identifying a software stock: Do’s and don’ts

As global economies are getting more integrated, technology companies are finding it an onerous task to align to the changing realities. In such a scenario, analyzing stocks from the technology sector require utmost caution and understanding. We will, in this article, try to elucidate the factors one should keep in mind before investing in a software sector company.

Profile
Large english speaking population and low employee costs compared to developing countries have been the foundations upon which the Indian software sector has evolved over the years. Software sector sells man-hours i.e. its earnings are from billing rates (dollars/rupees earned per hour of work) multiplied by number of hours worked by an employee in a year. However, there is one critical factor here. A software company can increase revenues by adding employees and/or by increasing utilization (number of employees actually working on projects as a percentage of total employee base) and/or by charging more per hour (i.e. billing rate).

THE LEFT-HAND SIDE (Hours Worked)

Scalability
Not every software company has systems in place to manage large addition in employees per annum. A company can increase its staff strength to say 3,000 in the first three years. However, to increase the number to 6,000, the business model should be robust. Scalability therefore, is of high significance. To succeed on the scalability front, a software company needs to figure out the kind of capacity (physical infrastructure like development centres, marketing and distribution channels), people, and technology it needs to invest in. However, the most important aspect of scalability is to make sure that employees are absorbed and trained (including the understanding of the company’s culture and values).

Utilisation
Another aspect of scalability is the level of utilisation. A software company needs to make sure that its capacity is utilized as effectively and fully as possible. This will result in revenue maximization and higher productivity per employee. But both the factors listed above depend on the management vision, talent and ability to foresee future industry trends.

Employee retention
Owing to increasing competition for talent, the need to reward employees for the value they create is another critical factor that determines sustainable growth. The need to attract proper talent and retain it gains utmost importance. Software companies’ resort to measure like performance based incentives and ESOPs to reward their employees.

THE RIGHT-HAND SIDE (Billing Rates)

Having looked at factors that influences hours worked per annum, consider billing rates now.

The value-chain
Put simply, value chain has low-value add services like body shopping at the bottom of the chain to products at the higher-end . Moving up the value chain is delivering a service or product for which the customer is willing to pay a higher price because he perceives a higher value. However, moving up the value chain involves a whole set of issues. While marketing and branding play a key role, delivery of services is even more important. One way to measure the delivery strength of a software company is revenues from repeat business (basically, satisfied customers). Moving up the chain is an ongoing process. It takes time for a company to attain critical mass before it has the ability to bid for large value-add contracts.

Onsite and offshore
As per the outsourcing model, employees and their efforts are divided into two elements – onsite (at clients’ location) and offshore (at company’s premises). Although most of the Indian software majors are growing, success depends much on the way these onsite and offshore efforts are integrated in the most efficient manner to provide seamless services to clients. While onsite involves higher billing rates, offshore offers higher margins because costs are relatively lower.

Competition
Competition, both from domestic players and global players, also has a bigger say in billing rates. Since Indian companies are miniscule when viewed on the global scale, the bargaining power is on the lower side. Competition has surfaced from global majors setting up development centres in India in an effort to replicate the Indian offshoring model. Another thing to note here is, the higher a company is in the value chain, the lower the competition.

Key things to look at before investing in a software stock

·         Management:  A management with vision is one of the major competitive advantages. Since the software sector is dynamic in nature, management quality has a high weightage. The ability to foresee threats/opportunities without diverting from the vision is important. Retail investor could gauge this from how the company has performed in a downturn/upturn compared to its peers in their respective competencies. Scanning the companies’ annual reports or the official web site also gives an indication of the management’s future vision.

·         Employee productivity:  Productivity (revenue per employee divided by cost per employee) indicates how much value a company’s employees are adding relative to the costs that are incurred on them. These are relative terms and have to be compared with the peer group.

·         Revenue concentration:  Since this industry has a high risk-profile, it becomes important to understand from where (geographical mix), from whom (client concentration) and how (industry verticals) is the company generating its revenues. Though few clients accounting for larger share of revenue is not necessarily a negative, diversification insulates a software company from volatility. Remember, earnings visibility in the sector is relatively poor.

·         Financial ratios:  Some quantitative measures evaluating a software company stock are P/E (relative to the sector), Return on Equity, Return on Assets and Return on Capital (for profitability) and Operating margins (for efficiency). Some companies command a higher premium due to subjective factors like management quality and their position on the value chain.

A final note: Global IT spending and a move towards outsourcing

Apart from the inherent features as mentioned above, there are a few external factors like the level of global IT spending and the percentage share India is likely to get from the same (simply, move towards outsourcing). At some point, the advantage of low employee costs could dry out and the sector could get commoditised. Besides, India has competition from the likes of China and South East Asia as other outsourcing destinations.

So, building a competitive advantage is very important and for that, management quality plays a vital role. Investors do need to apply great caution before investing into software stocks.

 

India_Bull forever Bull !
www.kapilcomedynights.com
IP IP Logged
omshivaya
Senior Member
Senior Member
Avatar

Joined: 06/Sep/2006
Location: India
Online Status: Offline
Posts: 5966
Quote omshivaya Replybullet Posted: 01/Feb/2007 at 1:49am
Sandeep, keep a difference of 1 minutes between each posting. Dont post too fast. Post one, count to 20...then post two, count to 20....then post three: and so on and so forth. No worries...!
The most important quality for an investor is temperament,not intellect.A temperament that neither derives great pleasure from being with the crowd nor against it
IP IP Logged
<< Prev Page  of 6 Next >>
Post Reply Post New Topic
Printable version Printable version

Forum Jump
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot delete your posts in this forum
You cannot edit your posts in this forum
You cannot create polls in this forum
You cannot vote in polls in this forum



This page was generated in 0.078 seconds.
Bookmark this Page